In the context of recent outbreaks of monkeypox virus (MPXV) infection outside African endemic areas, the HCSP proposes the implementation of measures for preventing the transmission of MPXV through blood products, grafts and other human body products and components (HBCPs).

Based on available data on the modes of transmission of MPXV, diagnostic methods, persistence of MPXV in the human body, virus inactivation procedures and international recommendations, the HCSP recommends the followings:

1) For contacts who have received the Imvanex© vaccine, deferral of human body products donation for a period of 4 weeks after the last dose of vaccine.

2) For blood and organ, tissue and cell donors:

• a 21-day deferral of donation for persons identified as contact cases,
• a 42-day deferral of donation for persons with confirmed MPXV infection.

However, these recommendations take into account specific situations:

• in case of vital emergency (heart and liver) for organ donations from donors with confirmed, probable or suspected infection, to perform an orthopoxvirus PCR testing on blood, subject to being able to provide the result within the given timeframe, and to assess the benefit/risk ratio on a case by case basis;
• if it is not possible to defer a hematopoietic stem cell transplant, to make available the result of an orthopoxvirus PCR test on blood;
• in the presence of elements in favor of MPXV infection in deceased donors, to exclude them definitively from organ, tissue or cell donation.

3) For assisted reproduction, persons with confirmed MPXV infection are deferred 42 days from the date of onset of clinical signs and those identified as contact cases are deferred 21 days from the date of last contact.

For fertility preservation, the sample is deferred whenever possible or otherwise frozen (an orthopoxvirus PCR test will be performed at the time of thawing).